| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/16/2011 | CA2401624C Photodynamic cellular and acellular organism eradication utilizing a photosensitive material and surfactant |
| 08/16/2011 | CA2400639C Compounds with 5-ht1a activity useful for treating disorders of the outer retina |
| 08/16/2011 | CA2397590C Antisense inhibition of ptp1b expression |
| 08/16/2011 | CA2386960C Method for preparing a composition by mother-of-pearl extraction, comprising the mother-of-pearl integral components, composition obtained by said method and it's use in cosmetic and dermatology |
| 08/16/2011 | CA2382941C Use of leptin in inhibition of endothelial cell proliferation |
| 08/16/2011 | CA2376164C Intermolecularly associating compounds, and aggregates comprising them |
| 08/16/2011 | CA2369270C Camptothecin analogs and methods of preparation thereof |
| 08/16/2011 | CA2354325C Growth factor homolog zvegf3 |
| 08/16/2011 | CA2321837C Systemic delivery of serum stable plasmid lipid particles for cancer therapy |
| 08/16/2011 | CA2174928C Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| 08/12/2011 | DE202010007074U1 Neue Darreichungsformen für Cineol New forms of cineole |
| 08/11/2011 | WO2011097617A2 Compositions and methods for reducing appearance of under-eye dark circles |
| 08/11/2011 | WO2011097614A1 Mehods and compositions useful in diseases or conditions related to repeat expansion |
| 08/11/2011 | WO2011097607A1 Anti-viral treatment and assay to screen for anti-viral agent |
| 08/11/2011 | WO2011097594A2 Therapeutic methods and compositions involving allosteric kinase inhibition |
| 08/11/2011 | WO2011097577A2 Compositions and methods for treating or preventing retinal degeneration |
| 08/11/2011 | WO2011097571A2 Methods for the use of progestogen as a glucocorticoid sensitizer |
| 08/11/2011 | WO2011097553A1 Pyridazine derivatives useful as cannabinoid - 2 agonists |
| 08/11/2011 | WO2011097549A2 Treatment skin disorders |
| 08/11/2011 | WO2011097526A1 Compounds and compositions as protein kinase inhibitors |
| 08/11/2011 | WO2011097525A1 Solid state forms of macrocyclic kinase inhibitors |
| 08/11/2011 | WO2011097522A2 Combination methods for treatment of disease |
| 08/11/2011 | WO2011097496A1 Selective androgen receptor modulators |
| 08/11/2011 | WO2011097491A1 Benzimidazole antiviral agents |
| 08/11/2011 | WO2011097456A2 Compositions and methods for enhanced parvovirus transduction |
| 08/11/2011 | WO2011097407A1 Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
| 08/11/2011 | WO2011097388A1 Selective inhibition of polyglutamine protein expression |
| 08/11/2011 | WO2011097372A2 Pterostilbene cocrystals |
| 08/11/2011 | WO2011097347A2 Bismuth-thiols as antiseptics for biomedical uses, including treatment of bacterial biofilms and other uses |
| 08/11/2011 | WO2011097342A1 Hydrophobically-modified hyaluronan and methods of making and using thereof |
| 08/11/2011 | WO2011097336A2 Highly selective 5-ht(2c) receptor agonists having antagonist activity at the 5-ht(2b) receptor |
| 08/11/2011 | WO2011097333A1 Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors |
| 08/11/2011 | WO2011097331A1 Crystalline forms of (s)-1-(4-(5-cyclopropyl-1h-pyrazol-3- ylamino)pyrrolo [1,2-f] [1,2,4] triazin-2-yl)-n-(6-fluoropyridin- 3-yl)-2-methylpyrrolidine-2-carboxamide |
| 08/11/2011 | WO2011097327A2 Compositions and methods of modulating receptor protein tyrosine phosphatases |
| 08/11/2011 | WO2011097324A1 Polysaccharide based antimicrobial formulations |
| 08/11/2011 | WO2011097317A1 Use of n1,n4-bis[3-(ethylamino)propyl]-2-butene-1,4-diamine compounds in combination with epigenetic-acting pharmaceuticals for enhanced cancer therapy |
| 08/11/2011 | WO2011097300A1 Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| 08/11/2011 | WO2011097273A1 Methods and compositions for treating non-alcoholic fatty liver disease with docosahexaenoic acid and n-acetyl lcystenine |
| 08/11/2011 | WO2011097269A1 Crystallization method and bioavailability |
| 08/11/2011 | WO2011097233A1 Fatty acid amide hydrolase inhibitors |
| 08/11/2011 | WO2011097221A2 Methods of promoting tissue growth and tissue regeneration |
| 08/11/2011 | WO2011097218A1 Anti-cancer therapeutic agents |
| 08/11/2011 | WO2011097166A2 Combination therapy for treating cancer comprising an igf-1r inhibitor and an hdac inhibitor |
| 08/11/2011 | WO2011097149A2 Taxane-and taxoid-protein compositions |
| 08/11/2011 | WO2011097148A2 Use of oral heparin preparations to treat urinary tract diseases and conditions |
| 08/11/2011 | WO2011097087A1 Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
| 08/11/2011 | WO2011097079A1 Apoptosis signal-regulating kinase 1 inhibitors |
| 08/11/2011 | WO2011096953A1 Oral antidepressant formulation with reduced excipient load |
| 08/11/2011 | WO2011096950A1 Compositions and methods for treating obesity and obesity-related conditions |
| 08/11/2011 | WO2011096947A1 Optically pure diastereomers of 10-propargyl-10-deazaaminopterin and methods of using same |
| 08/11/2011 | WO2011096941A1 Method of treating ocular allergy |
| 08/11/2011 | WO2011096909A1 Pharmaceutical compositions comprising fluticasone, tiotropium and sodium cromoglycate |
| 08/11/2011 | WO2011096809A1 Use of sialyl oligosaccharides to modulate the immune system |
| 08/11/2011 | WO2011096808A1 Use of sialyl oligosaccharides in weight management |
| 08/11/2011 | WO2011096688A2 Composition for improving scalp and hair health comprising a dibenzo-p-dioxin derivative |
| 08/11/2011 | WO2011096676A2 Indirubin-3'-oxime derivatives as potent cyclin dependent kinase inhibitors |
| 08/11/2011 | WO2011096665A2 Complex formulation comprising aspirin coated with barrier containing hydrophobic additive, and hmg-coa reductase inhibitor |
| 08/11/2011 | WO2011096642A2 Pharmaceutical composition for preventing and treating inflammatory diseases |
| 08/11/2011 | WO2011096602A1 Glycine which enhances neutrophil microbicidal activity |
| 08/11/2011 | WO2011096566A1 Adhesive patch for treatment of tinea unguium |
| 08/11/2011 | WO2011096536A1 Novel synthetic glycolipid and use thereof |
| 08/11/2011 | WO2011096535A1 Pharmaceutical agent for treatment and/or prevention of cancer |
| 08/11/2011 | WO2011096513A1 Eye drops |
| 08/11/2011 | WO2011096490A1 Imidazopyridin-2-one derivative |
| 08/11/2011 | WO2011096484A1 Read through inducer, and therapeutic agent for nonsense-mutation-type genetic diseases |
| 08/11/2011 | WO2011096462A1 Heterocyclic compound having npy y5 receptor antagonistic activity |
| 08/11/2011 | WO2011096461A1 Quinoline derivative |
| 08/11/2011 | WO2011096413A1 Agent for improving motility function |
| 08/11/2011 | WO2011096377A1 Pyrrole compound |
| 08/11/2011 | WO2011096374A1 Novel iodobenzyl-bleomycin compound |
| 08/11/2011 | WO2011096360A1 Method for treatment of lacto-n-biose-containing solution |
| 08/11/2011 | WO2011096211A1 Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis |
| 08/11/2011 | WO2011096210A1 Prmt1 and prmt6 for target genes of cancer therapy and diagnosis |
| 08/11/2011 | WO2011096196A1 Lsd1 for target genes of cancer therapy and diagnosis |
| 08/11/2011 | WO2011095997A1 Benzamide compounds as glucokinase activators and their pharmaceutical application |
| 08/11/2011 | WO2011095987A1 Novel process for the preparation of cis-nucleoside derivative |
| 08/11/2011 | WO2011095973A1 Extended release formulations of rasagiline and uses thereof |
| 08/11/2011 | WO2011095893A1 Synthesis of dgjnac from d-glucuronolactone and use to inhibit alpha-n-acetylgalactosaminidases |
| 08/11/2011 | WO2011095882A1 Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency |
| 08/11/2011 | WO2011095837A1 Docosahexaenoic acid ethyl esters and/or its derivatives for prevention and/or treatment of age-related macular degeneration |
| 08/11/2011 | WO2011095835A1 Highly pure imatinib or a pharmaceutically acceptable salt thereof |
| 08/11/2011 | WO2011095814A1 Treatment of respiratory disorders |
| 08/11/2011 | WO2011095807A1 Combinations of mek and hh inhibitors |
| 08/11/2011 | WO2011095803A1 Hplc method for analyzing frovatriptan |
| 08/11/2011 | WO2011095802A1 Hplc method for analyzing sunitinib |
| 08/11/2011 | WO2011095801A2 Pharmaceutical composition |
| 08/11/2011 | WO2011095764A2 Antimicrobial compounds |
| 08/11/2011 | WO2011095736A1 Branched soluble glucose polymers for peritoneal dialysis |
| 08/11/2011 | WO2011095668A1 Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid |
| 08/11/2011 | WO2011095625A1 1,2,4-triazine-4-amine derivatives |
| 08/11/2011 | WO2011095593A1 Iodo precursor for a pet imaging agent of amyloid plaques |
| 08/11/2011 | WO2011095588A1 Pharmaceutical composition comprising n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamid |
| 08/11/2011 | WO2011095585A1 Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof |
| 08/11/2011 | WO2011095584A1 Sigma ligands for use in the prevention and/or treatment of postoperative pain |
| 08/11/2011 | WO2011095581A1 S piroindoline compounds for use as anthelminthi cs |
| 08/11/2011 | WO2011095579A1 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride polymorphs and solvates |
| 08/11/2011 | WO2011095576A1 Compounds for the treatment and prevention of influenza |
| 08/11/2011 | WO2011095556A1 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds |
| 08/11/2011 | WO2011095553A1 Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction |
| 08/11/2011 | WO2011095535A2 Pyrrolidine derivatives |